MST-02
Migraine
PreclinicalActive
Key Facts
About Miist Therapeutics
Miist Therapeutics is pioneering an inhaled microparticle drug delivery platform to treat acute conditions with an onset of action measured in seconds, not hours. Its lead program, MST-02 for migraine, is preparing for Phase 1/2 clinical trials, with a pipeline planned for other acute indications. The company, which raised a $7M funding round, leverages a novel approach to aerosol generation to create rapidly absorbed particles, positioning itself to address a significant unmet need for fast-acting therapies in multi-billion dollar markets.
View full company profileOther Migraine Drugs
| Drug | Company | Phase |
|---|---|---|
| Naratriptan N‑Nitroso Impurity | Synthink Research Chemicals | Reference Standard |
| Migraine Clinical Trials | DM Clinical Research | Not Specified |
| Sumatriptan Alginate Film | Klaria | Not Specified (Clinical) |
| DerMap™ Platform | ArrayPatch | Research |
| Relonova (Rizatriptan) | NovaMedica | Approved |
| Symbravo (AXS-07) | Axsome Therapeutics | Approved |
| EVO756 | Evommune | Phase 1 |